MDMB-5'Br-4en-PINACA

MDMB-5'Br-4en-PINACA
Identifiers
IUPAC name
  • methyl (2S)-2-[(5-bromo-1-pent-4-enylindazole-3-carbonyl)amino]-3,3-dimethylbutanoate
PubChem CID
ChemSpider
Chemical and physical data
FormulaC20H26BrN3O3
Molar mass436.350 g·mol−1
3D model (JSmol)
SMILES
  • CC(C)(C)[C@@H](C(=O)OC)NC(=O)C1=NN(C2=C1C=C(C=C2)Br)CCCC=C
InChI
  • InChI=1S/C20H26BrN3O3/c1-6-7-8-11-24-15-10-9-13(21)12-14(15)16(23-24)18(25)22-17(19(26)27-5)20(2,3)4/h6,9-10,12,17H,1,7-8,11H2,2-5H3,(H,22,25)/t17-/m1/s1
  • Key:QQPVWGDNYWFMDE-QGZVFWFLSA-N

MDMB-5'Br-4en-PINACA is an indazole-3-carboxamide based synthetic cannabinoid receptor agonist that has been sold as a designer drug. It was first identified in Germany in November 2024. It is believed to be synthesized from the "half finished" synthesis precursor MDMB-5Br-INACA, which is shipped to the destination and then the final synthetic step is completed on arrival.[1]

See also

References

  1. ↑ "European Drug Report 2025 – Full Book" (PDF). European Union Drugs Agency (euda.europa.eu). 6 June 2025.


This article is issued from WikiProjectMed. The text is available under Creative Commons Attribution-ShareAlike License unless otherwise noted. Additional terms may apply for the media files.